164 related articles for article (PubMed ID: 37335087)
1. Dissecting the alternation landscape of mitochondrial metabolism-related genes in lung adenocarcinoma and their latent mechanisms.
Jin X; Liu D; Kong D; Zhou X; Zheng L; Xu C
Aging (Albany NY); 2023 Jun; 15(12):5482-5496. PubMed ID: 37335087
[TBL] [Abstract][Full Text] [Related]
2. Immune infiltration landscape on prognosis and therapeutic response and relevant epigenetic and transcriptomic mechanisms in lung adenocarcinoma.
Zhang L; Jiang B; Lan Z; Yang C; Yao Y; Lin J; Wei Q
Front Immunol; 2022; 13():983570. PubMed ID: 36275753
[TBL] [Abstract][Full Text] [Related]
3. Identification Six Metabolic Genes as Potential Biomarkers for Lung Adenocarcinoma.
Zhang S; Lu Y; Liu Z; Li X; Wang Z; Cai Z
J Comput Biol; 2020 Oct; 27(10):1532-1543. PubMed ID: 32298601
[TBL] [Abstract][Full Text] [Related]
4. Integrative Proteomic Characterization of Human Lung Adenocarcinoma.
Xu JY; Zhang C; Wang X; Zhai L; Ma Y; Mao Y; Qian K; Sun C; Liu Z; Jiang S; Wang M; Feng L; Zhao L; Liu P; Wang B; Zhao X; Xie H; Yang X; Zhao L; Chang Y; Jia J; Wang X; Zhang Y; Wang Y; Yang Y; Wu Z; Yang L; Liu B; Zhao T; Ren S; Sun A; Zhao Y; Ying W; Wang F; Wang G; Zhang Y; Cheng S; Qin J; Qian X; Wang Y; Li J; He F; Xiao T; Tan M
Cell; 2020 Jul; 182(1):245-261.e17. PubMed ID: 32649877
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Analysis of Alteration Landscape and Its Clinical Significance of Mitochondrial Energy Metabolism Pathway-Related Genes in Lung Cancers.
Ye Z; Zhang H; Kong F; Lan J; Yi S; Jia W; Zheng S; Guo Y; Zhan X
Oxid Med Cell Longev; 2021; 2021():9259297. PubMed ID: 34970420
[TBL] [Abstract][Full Text] [Related]
6. HMMR associates with immune infiltrates and acts as a prognostic biomaker in lung adenocarcinoma.
Ma X; Xie M; Xue Z; Yao J; Wang Y; Xue X; Wang J
Comput Biol Med; 2022 Dec; 151(Pt A):106213. PubMed ID: 36306573
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of a novel signature incorporating lipid metabolism and immune-related genes for assessing prognosis and immune landscape in lung adenocarcinoma.
Wang Y; Xu J; Fang Y; Gu J; Zhao F; Tang Y; Xu R; Zhang B; Wu J; Fang Z; Li Y
Front Immunol; 2022; 13():950001. PubMed ID: 36091041
[TBL] [Abstract][Full Text] [Related]
8. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of Fatty Acid Metabolism in Lung Adenocarcinoma to Guide Clinical Treatment.
Huang D; Tang E; Zhang T; Xu G
Front Immunol; 2022; 13():916284. PubMed ID: 35860256
[TBL] [Abstract][Full Text] [Related]
10. Prognostic model of lung adenocarcinoma constructed by the CENPA complex genes is closely related to immune infiltration.
Zhou H; Bian T; Qian L; Zhao C; Zhang W; Zheng M; Zhou H; Liu L; Sun H; Li X; Zhang J; Liu Y
Pathol Res Pract; 2021 Dec; 228():153680. PubMed ID: 34798483
[TBL] [Abstract][Full Text] [Related]
11. Identification of potential diagnostic and prognostic biomarkers for LUAD based on TCGA and GEO databases.
Zheng Q; Min S; Zhou Q
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34017995
[TBL] [Abstract][Full Text] [Related]
12. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.
Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ
Front Immunol; 2021; 12():724741. PubMed ID: 34335635
[TBL] [Abstract][Full Text] [Related]
13. EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltrates.
Fan K; Zhang BH; Han D; Sun YC
BMC Bioinformatics; 2023 Apr; 24(1):149. PubMed ID: 37069494
[TBL] [Abstract][Full Text] [Related]
14. Identification of potential tumor antigens and immune subtypes for lung adenocarcinoma.
Bai M; Liu X; Wang L
Med Oncol; 2023 Feb; 40(3):100. PubMed ID: 36809467
[TBL] [Abstract][Full Text] [Related]
15. Immune landscape and a novel immunotherapy-related gene signature associated with clinical outcome in early-stage lung adenocarcinoma.
Bao X; Shi R; Zhao T; Wang Y
J Mol Med (Berl); 2020 Jun; 98(6):805-818. PubMed ID: 32333046
[TBL] [Abstract][Full Text] [Related]
16. Subtype classification based on t cell proliferation-related regulator genes and risk model for predicting outcomes of lung adenocarcinoma.
Yang Q; Zhu W; Gong H
Front Immunol; 2023; 14():1148483. PubMed ID: 37077919
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis to identify a novel diagnostic marker of lung adenocarcinoma and its immune infiltration landscape.
Zhu A; Pei D; Zong Y; Fan Y; Wei S; Xing Z; Song S; Wang X; Gao X
Front Oncol; 2023; 13():1199608. PubMed ID: 37409245
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma.
Wang N; Chai M; Zhu L; Liu J; Yu C; Huang X
Front Immunol; 2023; 14():1070953. PubMed ID: 37334367
[TBL] [Abstract][Full Text] [Related]
19. Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis.
Zhu M; Zeng Q; Fan T; Lei Y; Wang F; Zheng S; Wang X; Zeng H; Tan F; Sun N; Xue Q; He J
Front Immunol; 2022; 13():783495. PubMed ID: 35222371
[TBL] [Abstract][Full Text] [Related]
20. Vesicle-mediated transport-related genes are prognostic predictors and are associated with tumor immunity in lung adenocarcinoma.
Qian C; Jiang Z; Zhou T; Wu T; Zhang Y; Huang J; Ouyang J; Dong Z; Wu G; Cao J
Front Immunol; 2022; 13():1034992. PubMed ID: 36524130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]